Results 1 - 20 of 27,662 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Show only
- Peer-reviewed Journals (26,047)
| Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
|---|---|---|---|
| 1 |
Material Type: Article
|
|
Lecanemab in Early Alzheimer’s DiseaseThe New England journal of medicine, 2023-01, Vol.388 (1), p.9-21 [Peer Reviewed Journal]Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;COPYRIGHT 2023 Massachusetts Medical Society ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2212948 ;PMID: 36449413Full text available |
| 2 |
Material Type: Article
|
|
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaThe New England journal of medicine, 2021-04, Vol.384 (14), p.1289-1300 [Peer Reviewed Journal]Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2035716 ;PMID: 33616314Full text available |
| 3 |
Material Type: Article
|
|
Dostarlimab for Primary Advanced or Recurrent Endometrial CancerThe New England journal of medicine, 2023-06, Vol.388 (23), p.2145-2158 [Peer Reviewed Journal]Copyright © 2023 Massachusetts Medical Society. All rights reserved. ;Copyright © 2023 Massachusetts Medical Society. ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2216334 ;PMID: 36972026Full text available |
| 4 |
Material Type: Article
|
|
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced CancersJournal of clinical oncology, 2019-04, Vol.37 (12), p.946-953 [Peer Reviewed Journal]2019 by American Society of Clinical Oncology 2019 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.18.02018 ;PMID: 30811285Full text available |
| 5 |
Material Type: Article
|
|
The antibody aducanumab reduces Aβ plaques in Alzheimer's diseaseNature (London), 2016-09, Vol.537 (7618), p.50-56 [Peer Reviewed Journal]ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/nature19323 ;PMID: 27582220Full text available |
| 6 |
Material Type: Article
|
|
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic LeukemiaCell stem cell, 2018-06, Vol.22 (6), p.951-959.e3 [Peer Reviewed Journal]2018 ;Copyright © 2018. Published by Elsevier Inc. ;ISSN: 1934-5909 ;EISSN: 1875-9777 ;DOI: 10.1016/j.stem.2018.05.018 ;PMID: 29859176Full text available |
| 7 |
Material Type: Article
|
|
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitorsBlood, 2019-12, Vol.134 (24), p.2127-2138 [Peer Reviewed Journal]2019 American Society of Hematology ;2019 by The American Society of Hematology. ;2019 by The American Society of Hematology 2019 ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2019001869 ;PMID: 31697801Full text available |
| 8 |
Material Type: Article
|
|
T-cell invigoration to tumour burden ratio associated with anti-PD-1 responseNature (London), 2017-05, Vol.545 (7652), p.60-65 [Peer Reviewed Journal]COPYRIGHT 2017 Nature Publishing Group ;COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group May 4, 2017 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/nature22079 ;PMID: 28397821Full text available |
| 9 |
Material Type: Article
|
|
Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisThe New England journal of medicine, 2013-08, Vol.369 (8), p.699-710 [Peer Reviewed Journal]Copyright © 2013 Massachusetts Medical Society. All rights reserved. ;2014 INIST-CNRS ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1215734 ;PMID: 23964932 ;CODEN: NEJMAGFull text available |
| 10 |
Material Type: Article
|
|
Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseThe New England journal of medicine, 2013-08, Vol.369 (8), p.711-721 [Peer Reviewed Journal]Copyright © 2013 Massachusetts Medical Society. All rights reserved. ;2014 INIST-CNRS ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1215739 ;PMID: 23964933 ;CODEN: NEJMAGFull text available |
| 11 |
Material Type: Article
|
|
Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?Blood, 2017-12, Vol.130 (23), p.2463-2468 [Peer Reviewed Journal]2017 American Society of Hematology ;2017 by The American Society of Hematology. ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2017-08-801662 ;PMID: 29042366Full text available |
| 12 |
Material Type: Article
|
|
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody SotrovimabNew England Journal of Medicine, 2021-11, Vol.385 (21), p.1941-1950 [Peer Reviewed Journal]Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2107934 ;PMID: 34706189Digital Resources/Online E-Resources |
| 13 |
Material Type: Article
|
|
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeThe New England journal of medicine, 2013-06, Vol.368 (23), p.2169-2181 [Peer Reviewed Journal]Copyright © 2013 Massachusetts Medical Society. All rights reserved. ;2014 INIST-CNRS ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1208981 ;PMID: 23738544 ;CODEN: NEJMAGFull text available |
| 14 |
Material Type: Article
|
|
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast CancerClinical cancer research, 2018-06, Vol.24 (11), p.2493-2504 [Peer Reviewed Journal]2018 American Association for Cancer Research. ;Copyright American Association for Cancer Research Inc Jun 1, 2018 ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.CCR-17-3322 ;PMID: 29476019Full text available |
| 15 |
Material Type: Article
|
|
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced CancerClinical cancer research, 2018-04, Vol.24 (8), p.1816-1823 [Peer Reviewed Journal]2018 American Association for Cancer Research. ;Copyright American Association for Cancer Research Inc Apr 15, 2018 ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.CCR-17-1922 ;PMID: 29549159Full text available |
| 16 |
Material Type: Article
|
|
A Monoclonal Antibody for Malaria PreventionThe New England journal of medicine, 2021-08, Vol.385 (9), p.803-814 [Peer Reviewed Journal]Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;COPYRIGHT 2021 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2034031 ;PMID: 34379916Full text available |
| 17 |
Material Type: Article
|
|
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaThe New England journal of medicine, 2020-05, Vol.382 (20), p.1894-1905 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1915745 ;PMID: 32402160Full text available |
| 18 |
Material Type: Article
|
|
Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaquesBlood, 2018-08, Vol.132 (6), p.662-666 [Peer Reviewed Journal]2018 American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood-2018-05-846428 ;PMID: 29954750Full text available |
| 19 |
Material Type: Article
|
|
Casirivimab/Imdevimab: First ApprovalDrugs (New York, N.Y.), 2021-11, Vol.81 (17), p.2047-2055 [Peer Reviewed Journal]The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 ;2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG. ;Copyright Springer Nature B.V. Nov 2021 ;ISSN: 0012-6667 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-021-01620-z ;PMID: 34716907Full text available |
| 20 |
Material Type: Article
|
|
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β 2 -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialThe Lancet (British edition), 2016-10, Vol.388 (10056), p.2115 [Peer Reviewed Journal]Copyright © 2016 Elsevier Ltd. All rights reserved. ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)31324-1 ;PMID: 27609408Full text available |
Results 1 - 20 of 27,662 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Personalize your results
Refine Search Results
Expand My Results
Show only
- Peer-reviewed Journals (26,047)
Refine My Results
Creation Date
- Before 1990 (9)
- 1990 To 1997 (75)
- 1998 To 2005 (1,748)
- 2006 To 2014 (14,394)
- After 2014 (11,431)
-
More options
New Records
- New From Last Month (72)
- New From Last 3 Month (271)
-
More options
Resource Type
- Articles (27,429)
- magazinearticle (59)
- Thesises (postgraduate) (45)
- Book Chapters (38)
- Web Resources (26)
- Reports (25)
- Books (12)
- Conference Proceedings (12)
- Images (6)
- Text Resources (4)
- Reviews (4)
- Videos (1)
- Datasets (1)
-
More options
Subject
- Humans (25,953)
- Science & Technology (24,041)
- Life Sciences & Biomedicine (23,315)
- Female (13,802)
- Antibodies, Monoclonal, Humanized (11,260)
- Male (10,627)
- Middle Aged (9,024)
- Antibodies, Monoclonal, Humanized - Therapeutic Use (8,825)
- Oncology (8,238)
- Adult (7,433)
- Aged (6,982)
- Treatment Outcome (6,608)
- Antibodies, Monoclonal - Therapeutic Use (6,460)
- Biological And Medical Sciences (4,827)
- Medical Sciences (4,722)
- Bevacizumab (4,586)
- Antibodies, Monoclonal, Humanized - Administration & Dosage (4,205)
- Animals (3,891)
- Antibodies, Monoclonal, Humanized - Adverse Effects (3,752)
- Medicine (3,302)
-
More options
Databases
- MEDLINE (26,459)
- ProQuest Central (13,997)
- GFMER Free Medical Journals (11,145)
- PubMed Central (8,465)
- DOAJ Directory of Open Access Journals (6,529)
- HighWire Press (Free Journals) (5,075)
- ROAD: Directory of Open Access Scholarly Resources (4,378)
- Springer Open Access Journals (2,226)
- Wiley Open Access Journals (1,652)
- ProQuest One Psychology (1,454)
- Open Access: Nature Open Access (1,140)
- IngentaConnect Free/Open Access Journals (874)
- Taylor & Francis Open Access Journals (650)
- BMJ Open Access Journals (485)
- Free E- Journals (452)
- Journals@Ovid Open Access Journal Collection Rolling (435)
- OUP_牛津大学出版社OA刊 (398)
- Freely Accessible Japanese Titles (394)
- Public Library of Science (PLoS) Journals Open Access (378)
- Hyper Article en Ligne (HAL) (Open Access) (290)
-
More options
Language
Journal Title
- Annals Of Oncology (558)
- Annals Of The Rheumatic Diseases (395)
- Blood (375)
- Clinical Cancer Research (651)
- Frontiers In Immunology (294)
- Journal Of Clinical Oncology (804)
- Plos One (350)
- Rheumatology (318)
- The Lancet Oncology (364)
- The New England Journal Of Medicine (657)
-
More options
|
||||
 |
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY |  |
(84-028) 37 755 057 | Feedback |
| 19 Nguyen Huu Tho St. Dist.7, HCM |  |
thuvien@tdtu.edu.vn | ||